Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-10-03
2009-12-22
Crane, Lawrence E (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S046000, C514S047000, C514S048000, C514S049000, C514S050000, C514S051000, C514S220000, C514S230500, C514S231500, C514S252120, C514S301000, C514S473000, C514S261100
Reexamination Certificate
active
07635690
ABSTRACT:
The present invention discloses a method for treating HIV that includes administering β-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 or the 172 codons of the reverse transcriptase region. Also disclosed is a method for using β-D-D4FC as “salvage therapy” to patients which exhibit drug resistance to other anti-HIV agents. β-D-D4FC can be used generally as salvage therapy for any patient which exhibits resistance to a drug that induces a mutation at other than the 70(K to N), 90 or the 172 codons.
REFERENCES:
patent: 3817982 (1974-06-01), Verheyden et al.
patent: 4522811 (1985-06-01), Eppstein
patent: 4725442 (1988-02-01), Haynes
patent: 4788181 (1988-11-01), Driscoll et al.
patent: 4891225 (1990-01-01), Langer
patent: 4963662 (1990-10-01), Matthes et al.
patent: 5034394 (1991-07-01), Daluge
patent: 5196438 (1993-03-01), Martin et al.
patent: 5366972 (1994-11-01), Hargrave et al.
patent: 5409810 (1995-04-01), Larder
patent: 5413999 (1995-05-01), Vacca et al.
patent: 5463092 (1995-10-01), Hostetler
patent: 5484926 (1996-01-01), Dressman et al.
patent: 5489593 (1996-02-01), Palmer et al.
patent: 5496935 (1996-03-01), Matthes et al.
patent: 5519021 (1996-05-01), Young et al.
patent: 5561120 (1996-10-01), Lin et al.
patent: 5563142 (1996-10-01), Palmer et al.
patent: 5585397 (1996-12-01), Tung et al.
patent: 5604209 (1997-02-01), Ubasawa et al.
patent: 5627160 (1997-05-01), Lin et al.
patent: 5631239 (1997-05-01), Lin et al.
patent: 5703058 (1997-12-01), Liotta et al.
patent: 5756478 (1998-05-01), Cheng et al.
patent: 5869461 (1999-02-01), Cheng et al.
patent: 5905070 (1999-05-01), Liotta et al.
patent: 6232300 (2001-05-01), Schinazi et al.
patent: 6391859 (2002-05-01), Schinazi et al.
patent: 7115584 (2006-10-01), Schinazi et al.
patent: 1620047 (1970-03-01), None
patent: 0409227 (1990-07-01), None
patent: 0515156 (1992-11-01), None
patent: 0519464 (1992-12-01), None
patent: 8901258 (1990-12-01), None
patent: WO 91/06554 (1991-05-01), None
patent: WO91/09849 (1991-07-01), None
patent: WO 91/16333 (1991-10-01), None
patent: WO 91/19727 (1991-12-01), None
patent: WO 94/14456 (1994-07-01), None
patent: WO 94/27616 (1994-12-01), None
patent: WO 95/07287 (1995-03-01), None
patent: WO 96/22778 (1996-08-01), None
patent: WO 96/28170 (1996-09-01), None
patent: WO 99/66936 (1999-12-01), None
(S) Romero et al., “Bis(heteroaryl)piperazine (BHAP) Reverse Transcriptase Inhibitors:” . . . , a Second Generation Clinical Candidate, Journal of Medicinal Chemistry, 36(10), 1505-1508 (May 14, 1993).
Ajmera, S., et al.,J. Med. Chem., 27(1):11-14 (1984).
Balzarini, J. et al.,Biochem. And Biophys. Res. Comm., 164(3): (1989).
Chang, C., et al.,J. of Med. Chem., 267(20):13938-13942 (1992).
Chen, S H et al., Synthesis and comparative evaluation of two antiviral agents: beta-L-Fd4C and beta-D-Fd4C,Bioorganic&Medicinal Chemistry Letters, GB, Oxford, 8(22):3245-3250 (Nov. 17, 1998).
Choi, W. et al.,Biorganic&Med. Chem. Letters, 3(4):693-696 (1993).
Coe, P.L.. et al.,J. Flourine Chem., 69(1):19-24 (1994).
Doong, S., et al.,Proc. Natl. Acad. Sci. (USA), 88:8495-8499 (1991).
Frick, L.W., et al.,AntiMicrob. Agents and Chemotherapy, 37(11):2285-2292 (Nov. 1993).
Hammer, S.M., “Advances in antiretroviral therapy and viral monitoring,”AIDS, 10(3):s1-s11 (1996).
Horwitz, J.P., et al.,Tetrah. Letters, 1964(38):2725-2727, (1964).
Hronowski, L.J.J., et al.,Can. J. Chem., 70(4):1162-1169 (1992).
Izuta, S., et al.,Nucleic Acids Symp. Ser.(Symp. Nucleic Acids Chem., 13th) 241-244 (1985).
Jeong, L.S., et al.,J. of Med. Chem., 36(2):181-195 (1993).
Khwaja, T.A., et al.,J. Med. Chem., 10(6):1066-1070 (1967).
Kim, H.O., et al.,J. of Med. Chem., 36(5):519-528 (1993).
Larder, B.A., et al.,Science, 243:1731-1734 (1989).
Mellors, J,W, et al.,Mol. Pharm., 41:446-451 (1992).
Nunberg, J.H., et al.,J. Virol.I, 65(9):4887-4892 (1991).
Richman, D., et al.,Proc. Natl. Acad. Sci. (USA), 88:11241-11245 (1991).
Schinazi, R.F. et al.,AntiMicrob. Agents and Chemotherapy, 36(11):2423-2431 (1992).
Schinazi, R.F. et al.,AntiMicrob. Agents and Chemotherapy, 38(9):2172-2174 (1994).
Schinazi, R.F., et al., “Mutations in retroviral genes associated with drug resistance: 2000-2001 update”International Antiviral News, 8(5): 65-91(2000).
Schinazi, R.F., et al.,Biochem. Pharma., 44(2):199-204 (1992).
Shigeta, S., et al.,J. Infect. Dis., 163(2):270-275 (1991).
Siddiqui, M.A., et al.,J. Med. Chem., 35(12):2195-2201 (1992).
St. Clair, M.H., et al.,Science, 253:1557-1559 (1991).
Van Aerschot, A., et al.,J. of Med. Chem., 33:1833-1839 (1990).
Van Draanen, N. A. et al.,AntiMicrob. Agents and Chemotherapy, 38(4):868-871 (1994).
Wilson, L.J., et al.,Biorganic&Med. Chem. Letters, 3(2):169-174 (1993).
Hammond Jennifer L.
Liotta Dennis C.
Mellors John W.
Schinazi Raymond F.
Crane Lawrence E
Emory University
King & Spalding
LandOfFree
HIV-1 mutations selected for by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV-1 mutations selected for by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV-1 mutations selected for by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4084578